Association of HBB Gene Polymorphisms Rs10768683, Rs1609812 and Rs334 with Transfusion-Dependent Beta-Thalassemia (TDT): A Case-Control Study

Why It Matters

Identifying HBB‑linked SNPs that influence TDT susceptibility enables more precise risk stratification and could inform personalized management strategies for beta‑thalassemia patients.

Key Takeaways

• rs1609812 GG genotype raises TDT risk ~3‑fold
• rs10768683 GC heterozygosity reduces TDT susceptibility
• rs334 (HbS) shows no significant link to TDT
• Study involved 400 patients and 400 matched controls
• All three SNPs deviated from Hardy‑Weinberg equilibrium

Pulse Analysis

Beta‑thalassemia remains a major public‑health challenge in regions with high carrier frequencies, and transfusion‑dependent forms (TDT) impose substantial clinical and economic burdens. While primary HBB mutations dictate baseline disease severity, secondary genetic modifiers can shift the phenotype dramatically. This Iranian case‑control investigation leveraged PCR‑RFLP and ARMS‑PCR to genotype three HBB polymorphisms, providing a robust dataset of 800 individuals that captures both hematologic profiles and iron‑overload metrics, such as serum ferritin levels exceeding 6,000 ng/mL. By adjusting for age and applying multiple inheritance models, the researchers isolated the independent contributions of each SNP.

The analysis revealed that the rs1609812 GG genotype confers roughly a threefold increase in TDT odds, a finding that persisted across codominant and recessive models. Conversely, carriers of the rs10768683 GC genotype experienced a 20‑25% reduction in risk, suggesting a protective heterozygote advantage. The classic sickle‑cell variant rs334 showed no meaningful association, highlighting that not all HBB‑linked variants affect thalassemia severity. Notably, all three loci departed from Hardy‑Weinberg expectations, hinting at possible selection pressures or population substructure within the studied cohort.

These results reinforce the concept that HBB‑linked single‑nucleotide polymorphisms act as modifiers of TDT susceptibility and may soon be integrated into genetic screening panels. Early identification of high‑risk genotypes could guide clinicians toward intensified monitoring, iron‑chelation therapy, or even gene‑editing interventions. Moreover, the protective signal from rs10768683 invites further functional studies to uncover underlying mechanisms, potentially unveiling new therapeutic targets. As precision medicine gains traction in hematology, incorporating such modifier data will be essential for tailoring treatment pathways and improving outcomes for beta‑thalassemia patients worldwide.